Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 3/20 | 0.61 |
| ▸ | CD40LG | P29965 | 3/20 | 0.61 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | FABP4 | P15090 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | TIMP3 | P35625 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14058895 | 0.85 | CD40 (0.56) | CD40CD40LGTTRFABP4CCNA2 | |
| SCHEMBL19020654 | 0.83 | CD40 (0.69) | CD40CD40LGTTRFABP4CCNA2 | |
| SCHEMBL11511725 | 0.82 | CD40 (0.69) | CD40CD40LGMEN1KMT2AALDH1A1 | |
| SCHEMBL6241585 | 0.82 | TIMP3 (0.56) | TIMP3MEN1KMT2ARECQLHSD17B10 | |
| SCHEMBL11759224 | 0.81 | TTR (0.59) | CD40CD40LGTTRFABP4CCNA2 | |
| SCHEMBL11466232 | 0.81 | TTR (0.52) | CD40CD40LGTTRFABP4CCNA2 | |
| SCHEMBL6244552 | 0.80 | CD40 (0.49) | CD40CD40LGTTRTIMP3MEN1 | |
| SCHEMBL26885009 | 0.79 | TTR (0.56) | CD40CD40LGTTRFABP4CCNA2 | |
| SCHEMBL19021224 | 0.79 | CD40 (0.92) | CD40CD40LGTTRFABP4CCNA2 | |
| SCHEMBL19020634 | 0.79 | CD40 (0.77) | CD40CD40LGTTRFABP4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315695-B1 | BENZENE TRICARBOXYLIC ACID AMIDES AS INSULIN RECEPTOR ACTIVATORS | TELIK INC (US) | 2005-07-13 | — | — | EP | claimed |
| US-6600069-B2 | Insulin receptor kinase activators; treating hyperglycemia; 4-((3,5-bis(N-(4-sulfophenyl)carbamoyl)phenyl)carbonylamino)-benzenesulfonic acid, for example | TELIK, INC. | 2003-07-29 | — | — | US | claimed |
| US-20020103183-A1 | Benzene tricarboxylic acid derivatives as insulin receptor activators | TELIK, INC. | 2002-08-01 | — | — | US | claimed |
| EP-1315695-B1 | BENZENE TRICARBOXYLIC ACID AMIDES AS INSULIN RECEPTOR ACTIVATORS | TELIK INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6600069-B2 | Insulin receptor kinase activators; treating hyperglycemia; 4-((3,5-bis(N-(4-sulfophenyl)carbamoyl)phenyl)carbonylamino)-benzenesulfonic acid, for example | TELIK, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20020103183-A1 | Benzene tricarboxylic acid derivatives as insulin receptor activators | TELIK, INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103183-A1 | Benzene tricarboxylic acid derivatives as insulin receptor activators | GPR119, INSR, IRS1 | CD40 1424/4885CD40LG 2403/4885TTR 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.